I-138

• CAT Number: I041282
• CAS Number: 2098211-50-6
• Molecular Formula: C26H23F3N6O
• Molecular Weight: 492.50
• Purity: ≥95%
• Synonyms: 9-[[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]-2-(2-propan-2-ylphenyl)-7H-purin-8-one
• InChI: InChI=1S/C26H23F3N6O/c1-15(2)18-6-4-5-7-19(18)22-30-12-20-24(33-22)35(25(36)31-20)13-16-8-10-17(11-9-16)23-32-21(14-34(23)3)26(27,28)29/h4-12,14-15H,13H2,1-3H3,(H,31,36)
• InChIKey: MVCJEDLGJGHLJM-UHFFFAOYSA-N
• SMILES: CC(C)C1=CC=CC=C1C2=NC=C3C(=N2)N(C(=O)N3)CC4=CC=C(C=C4)C5=NC(=CN5C)C(F)(F)F

I-138（Cat No.:I041282）is a novel therapeutic compound currently in preclinical development, designed to target and inhibit specific proteins involved in inflammation and immune response. It holds potential in treating autoimmune disorders, chronic inflammation, and other immune-related diseases by modulating the immune system’s overactive responses. I-138 works by disrupting the signaling pathways that lead to excessive inflammatory processes, potentially offering a safer and more effective treatment option for conditions like rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Its mechanism of action aims to reduce disease symptoms and improve patient quality of life.